Back to Search Start Over

Lost in translation: returning germline genetic results in genome-scale cancer research

Authors :
Hilda High
Jeremy L. Humphris
Lorraine A. Chantrill
Conrad Leonard
Marina Pajic
Annabel Goodwin
Nick Pavlakis
Sean M. Grimmond
Amber L. Johns
Andrew V. Biankin
Jaswinder S. Samra
David Miller
Karin S. Kassahn
Nikolajs Zeps
John V. Pearson
Skye McKay
Anthony J. Gill
Ann-Marie Patch
Mark Pinese
Katia Nones
Lesley Andrews
David K. Chang
Katherine M. Tucker
Nicola Waddell
Neil D. Merrett
R. Scott Mead
Source :
Genome Medicine, Vol 9, Iss 1, Pp 1-9 (2017), Genome Medicine
Publication Year :
2017
Publisher :
BMC, 2017.

Abstract

Background The return of research results (RoR) remains a complex and well-debated issue. Despite the debate, actual data related to the experience of giving individual results back, and the impact these results may have on clinical care and health outcomes, is sorely lacking. Through the work of the Australian Pancreatic Cancer Genome Initiative (APGI) we: (1) delineate the pathway back to the patient where actionable research data were identified; and (2) report the clinical utilisation of individual results returned. Using this experience, we discuss barriers and opportunities associated with a comprehensive process of RoR in large-scale genomic research that may be useful for others developing their own policies. Methods We performed whole-genome (n = 184) and exome (n = 208) sequencing of matched tumour-normal DNA pairs from 392 patients with sporadic pancreatic cancer (PC) as part of the APGI. We identified pathogenic germline mutations in candidate genes (n = 130) with established predisposition to PC or medium–high penetrance genes with well-defined cancer associated syndromes or phenotypes. Variants from candidate genes were annotated and classified according to international guidelines. Variants were considered actionable if clinical utility was established, with regard to prevention, diagnosis, prognostication and/or therapy. Results A total of 48,904 germline variants were identified, with 2356 unique variants undergoing annotation and in silico classification. Twenty cases were deemed actionable and were returned via previously described RoR framework, representing an actionable finding rate of 5.1%. Overall, 1.78% of our cohort experienced clinical benefit from RoR. Conclusion Returning research results within the context of large-scale genomics research is a labour-intensive, highly variable, complex operation. Results that warrant action are not infrequent, but the prevalence of those who experience a clinical difference as a result of returning individual results is currently low. Electronic supplementary material The online version of this article (doi:10.1186/s13073-017-0430-4) contains supplementary material, which is available to authorized users.

Details

Language :
English
Volume :
9
Issue :
1
Database :
OpenAIRE
Journal :
Genome Medicine
Accession number :
edsair.doi.dedup.....0937116ad528506af16b017843a93dd6